A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
Public ClinicalTrials.gov record NCT03215511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Study identification
- NCT ID
- NCT03215511
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 81 participants
Conditions and interventions
Conditions
Interventions
- Selitrectinib (BAY2731954) Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Month and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2017
- Primary completion
- Apr 10, 2022
- Completion
- Jan 29, 2023
- Last update posted
- Oct 29, 2024
2017 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ.of California-San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095-1781 | — |
| Stanford Cancer Center | Palo Alto | California | 94304 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30322 | — |
| Midwestern Regional Medical Center | Zion | Illinois | 60099 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114-2696 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03215511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03215511 live on ClinicalTrials.gov.